Pyrazole Derivatives as Kinase Inhibitors

Abstract

The present invention provides compounds having the general structure I, or a pharmaceutically acceptable salt thereof: wherein X is a six-member ring selected from phenyl, pyridine, or pyrimidine; Y is H, an alkenyl, a substituted alkenyl, or alkynyl, and R is H or alkyl. Pharmaceutical compositions for treating various disorders such as cancers, the compositions including compound I are also provided.

1 . A compound having the general structure I or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein: 
         X is a six-member ring selected from the group consisting of an unsubstituted phenyl, a substituted phenyl, an unsubstituted pyridine, a substituted pyridine, an unsubstituted pyrimidine and a substituted pyrimidine; 
         Y is selected from the group consisting of H, an unsubstituted alkenyl, a substituted alkenyl, an unsubstituted alkynyl and a substituted alkynyl; 
         and R is selected from the group consisting of H, an unsubstituted alkyl and a substituted alkyl. 
       
     
     
         2 . A pharmaceutical composition comprising a compound  claim 1  and a pharmaceutically acceptable carrier therefor. 
     
     
         3 . A method of treatment of a disorder, disease, or pathology, comprising administering a pharmacologically effective dose of a pharmaceutical composition of  claim 2  to a subject in need thereof, thereby treating the disorder, disease, or pathology. 
     
     
         4 . The method of  claim 3 , wherein the disorder, disease, or pathology is cancer.